Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

CRANBURY, N.J., Nov. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2011. Palatin reported a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the quarter ended September 30, 2011, compared to a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the same period in 2010.

The decrease in net loss for the quarter ended September 30, 2011, compared to the same period last fiscal year, is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.  The decrease in net loss per share was also significantly impacted by the higher number of shares outstanding in the quarter ended September 30, 2011 compared to the same period last fiscal year due primarily to the sale of shares of stock in March 2011.

REVENUERevenues for the quarter ended September 30, 2011 were $27,000, compared to $216,000 for the same period in 2010, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca AB.

COSTS AND EXPENSESTotal operating expenses for the quarter ended September 30, 2011 were $3.4 million, compared to $4.8 million for the comparable quarter of 2010. The decrease in operating expenses for the quarter is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and PL-3994 and preclinical development of an inhaled formul
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Calif. , April 20, 2015   Meditope ... products using its proprietary technology, today announced presentation of ... for the development of antibody-drug conjugates (ADCs). The data were ... 2015, taking place April 18-22 in Philadelphia ... about these data which point to the many commercial ...
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... developed a method for stacking synthetic DNA and carbon ... lead to more accurate measurements for research related to ... electrodes coated with enzymes that react with compounds and ... the inefficiency of those sensors leads to imperfect measurements. ...
... Alice Jacobs, CEO of IntelligentMDx (IMDx), was named Best Entrepreneur ... the eighth annual Stevie ® Awards for Women in ... Business honor women executives, entrepreneurs, and the companies they run ... programs, which have been hailed as the world,s premier business ...
... Ganey Associates, Inc. has announced its elite class of ... first-ever Summit and Top Improver awards for clinical achievement ... Centers. Press Ganey, the health care ... than 10,000 health care organizations worldwide to create and ...
Cached Biology Technology:New biosensor benefits from melding of carbon nanotubes, DNA 2Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business 2Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business 3Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 2Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 3
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... phosphatidylserine is a natural food supplement produced from beef, ... memory loss, it,s a popular treatment for older people ... Gil Ast and Dr. Ron Bochner of Tel Aviv ... discovered that the same supplement improves the functioning of ...
... Where? Copenhagen, Denmark: Bella Center Congress ... Why? An annual meeting focusing on ... installation, drawing on leading experiences from all over the world ... more than 900 abstracts received from more than 60 countries, ...
... University of Minnesota Medical School researchers from the Masonic ... University,s Brain Tumor Program, have developed a new mouse ... allow them to discover new genes and gene pathways ... published this week in the journal Nature Genetics ...
Cached Biology News:Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2
... Anti-Lipid Phosphate Phosphatase 2 ... buffered aqueous solution ... saline containing 0.08% sodium ... from the human LPP2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... mM NaCl, 10 mM sodium ... glycerol, pH 7.5. Recognizes the ... kinase 2 (MAPKAPK-2) protein phosphorylated ...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Biology Products: